Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

BACKGROUND: Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: File, Thomas M, Goldberg, Lisa, Das, Anita, Sweeney, Carolyn, Saviski, John, Gelone, Steven P, Seltzer, Elyse, Paukner, Susanne, Wicha, Wolfgang W, Talbot, George H, Gasink, Leanne B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853694/
https://www.ncbi.nlm.nih.gov/pubmed/30722059
http://dx.doi.org/10.1093/cid/ciz090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853694/
https://www.ncbi.nlm.nih.gov/pubmed/30722059
http://dx.doi.org/10.1093/cid/ciz090

Ejemplares similares